Literature DB >> 8549316

The antimicrobial activity of sparfloxacin, a new quinolone.

A G Paradelis1, K Delidou, A Grigoriadou, G Salpigides, A Pangalis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549316     DOI： 10.2165/00003495-199500492-00054

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  2 in total

1.  A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra-abdominal infections. Report from a Swedish Study Group.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

2.  In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

Authors:  S Nakamura; A Minami; K Nakata; N Kurobe; K Kouno; Y Sakaguchi; S Kashimoto; H Yoshida; T Kojima; T Ohue
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191
  2 in total
  2 in total

1.  Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.

Authors:  D Henry; W Ellison; J Sullivan; D L Mansfield; D J Magner; M B Dorr; G H Talbot
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 2.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.